GlobeNewswire

2018 World Salt Symposium

Dela

Groundbreaking Evidence on Salt and Health to be presented

Naples, FL, USA, Aug. 14, 2017 (GLOBE NEWSWIRE) -- The Tenth World Salt Symposium will be held June 19-21, 2018 in Park City, Utah, and will feature nearly 100 presentations from around the globe covering all topics related to salt. Starting in the 1960's, people from around the world have gathered to share information on the health benefits and uses of salt, salt mining practices, and solar salt production. The last such meeting was held in Beijing, China in 2009. The extended period between these conferences ensures a far-reaching and inclusive technical content. This is, without doubt, the most important international meeting focused on the subject of salt.

The Tenth World Salt Symposium is organized by the Salt Institute, in cooperation with several other salt organizations around the world. The World Salt Symposium focuses on the latest research and development in the international salt sector. It covers a wide spectrum of subjects, embracing the science, engineering, technology, economics and history of all forms of sodium chloride salt and their uses. As a broad international platform, the 2018 World Salt Symposium will enable researchers, producers and users of salt to become acquainted with the latest developments and technologies in this important industrial area.

Groundbreaking Evidence on Salt and Health

In the field of Salt and Health, we are pleased to announce that the following world-renowned experts, who have made unparalleled contributions to the field, have already committed to be keynote speakers at the upcoming symposium:

  • Dr. Michael Alderman, Albert Einstein College of Medicine, is editor of the American Journal of Hypertension, a fellow of the American College of Physicians, a member of the Association of American Physicians, and a past president of both the American Society of Hypertension and the International Society of Hypertension.
  • Dr. David McCarron, Research Associate in the Department of Nutrition, University of California-Davis and former Head of the Nephrology Division at Oregon Health & Science University. Dr. McCarron is a Fellow in the American College of Physicians and the AHA Council for High Blood Pressure Research. Dr. McCarron is the Chair of the Medical Nutrition Council of the American Society of Nutrition and a member of its Board of Directors.
  • Dr. Andrew Mente, Principal Investigator for the Epidemiology program at the Population Health Research Institute in Canada.
  • Dr. Suzanne Oparil, Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology, Section Chief of Vascular Biology and Hypertension and Director of the Vascular Biology and Hypertension Program of the Division of Cardiovascular Disease in the Department of Medicine at the University of Alabama at Birmingham (UAB).
  • Dr. Jan Staessen, head of Hypertension and Cardiovascular Epidemiology in the Biomedical Sciences Group at KU Leuven University in Copenhagen.

In the field of Salt and Health we will also have special sessions with iodine experts. 

Salt Production Sessions

The Salt Production track of the symposium will cover a broad range of topics relating to all aspects of salt production, including mine safety, history of salt production, solar salt issues and possibilities for value added products in the salt marketplace. More than 60 papers will be presented in podium sessions and poster sessions, along with discussion sessions on safety topics. This will make the World Salt Symposium the global forum of choice for discussions on salt production.

Salt and the Environment

The Salt and the Environment track of the symposium will cover several topics that include a number of sessions and keynotes on the benefits of technological developments to the use of rock salt in winter maintenance and how these developments move forward the concept of safe and sustainable snowfighting. Additionally, several sessions will look at ways in which the salt production industry has worked to ensure that the various processes of producing salt also provide substantial environmental benefits.

"We are pleased to bring the World Salt Symposium back to the United States and to host this important event. The Salt Institute is also happy to announce that we have made our 55-year-old World Salt Symposia archive available on a new website that will serve as a permanent and public archive of all past and future papers presented at World Salt Symposia," said Lori Roman, President of the Salt Institute.

With over 300 flights arriving daily on nine airlines, Salt Lake City International Airport is just 45 minutes from Park City. Park City, Utah, is known for summer and winter beauty as well as its world renowned skiing, the Sundance Film Festival which draws celebrities from around the world, or the Utah Olympic Park. But summer time visitors can also experience the beautiful mountains, national parks, lakes, waterfalls and rivers which surround Park City. Registration, hotel and meeting agenda is available online at http://www.worldsaltsymposium.org/next-symposium/.

-30-

The Salt Institute is a North American based non-profit trade association dedicated to advancing the many benefits of salt, particularly to ensure winter roadway safety, quality water and healthy nutrition.

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/e3839002-a53b-4984-8126-92572bed3cb8

Jorge Amselle
Salt Institute
239-231-3305
jorge@saltinstitute.org




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Salt Institute via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Oboya participates in China International Import Expo1.11.2018 15:00Pressmeddelande

Newsletter Lerum, 1th November 2018 Oboya Horticulture Industries AB (publ) ("Oboya"), a global manufacturer and supplier of products and services for the cultivation industry, will participate in China International Import Expo in Shanghai, China. China International Import Expo (CIIE) is a six-day fair held from November 5 to November 10, 2018 at the National Convention & Exhibition Center in Shanghai, China. This fair brings together companies, exhibitors and professional buyers from all over the world. The fair creates new channels for companies from different countries and regions and provides the opportunity to do business, strengthen cooperation and promote trade. Oboya's strategy is to work globally in the various markets in the cultivation and flower industry, which it's important for Oboya to participate in the major trade shows. Oboya has its own booth at the fair and will show/marketing the European cultivation products and technology to the Chinese market. The purpose of t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum